BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261204
DTSTAMP:20260805T090545Z
CREATED:20260805T090501Z
LAST-MODIFIED:20260805T090545Z
UID:44111-1796083200-1796342399@www.pharmajournalist.com
SUMMARY:8th CNS Drug Delivery Summit
DESCRIPTION:The 8th CNS Drug Delivery Summit is the leading industry forum dedicated to overcoming the challenges of delivering therapeutics across the blood-brain barrier and into the central nervous system. \nBringing together experts from biopharma\, biotech\, and academia\, the summit will explore the latest advances in drug delivery technologies\, including nanoparticles\, antibody shuttles\, gene therapy vectors\, focused ultrasound\, and intranasal delivery. Attendees will gain practical insights into improving drug penetration\, optimising biodistribution\, and advancing therapies for neurological and neurodegenerative diseases. \nThrough scientific presentations\, case studies\, and interactive discussions\, the event will address key translational\, clinical\, manufacturing\, and regulatory challenges while showcasing innovative approaches that can accelerate CNS drug development. \nJoin a collaborative community of drug developers\, technology innovators\, and scientific leaders committed to unlocking the next generation of CNS therapies and improving outcomes for patients worldwide. \nFind out more today: https://ter.li/08gi5jio
URL:https://www.pharmajournalist.com/event/8th-cns-drug-delivery-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261204
DTSTAMP:20260821T102547Z
CREATED:20260821T102547Z
LAST-MODIFIED:20260821T102547Z
UID:44216-1796083200-1796342399@www.pharmajournalist.com
SUMMARY:4th Cell Therapy for Autoimmune Disease Summit
DESCRIPTION:The 4th Cell Therapy for Autoimmune Disease Summit is the premier industry forum uniting biopharma leaders\, clinical innovators\, and scientific pioneers dedicated to advancing the next generation of cell therapies for autoimmune diseases. As the field progresses beyond early proof-of-concept studies and begins to generate increasingly robust clinical data\, organizations are shifting their focus toward the critical challenges that will determine long-term success. These include identifying optimal targets\, improving clinical translation\, enhancing manufacturing scalability\, ensuring patient safety\, navigating evolving regulatory pathways\, and developing sustainable commercialization strategies. \nTaking place December 1-3\, 2026\, in Philadelphia\, the summit provides a unique opportunity for stakeholders across biotech\, pharma\, academia\, translational research\, and clinical development to come together and share lessons learned from the forefront of autoimmune cell therapy innovation. With increasing momentum behind cell-based approaches for autoimmune indications\, attendees will gain practical insights into how leading organizations are overcoming development hurdles and positioning their programs for future success. \nThe agenda showcases the latest breakthroughs across a range of therapeutic modalities\, including CAR-T\, NK\, Treg\, MSC\, and emerging in vivo cell therapy approaches. Expert speakers from organizations such as Artiva Biotherapeutics\, Kite Pharma\, Cabaletta Bio\, Sail Biomedicines\, Mesoblast\, Orca Bio\, and other leading innovators will present real-world case studies\, clinical updates\, and strategic perspectives. Discussions will focus on analyzing increasingly mature clinical datasets\, expanding cell therapy applications beyond oncology\, exploring novel targets beyond CD19\, leveraging biomarkers and endpoints to optimize development\, and creating scalable manufacturing and delivery strategies to bring therapies to larger patient populations. \nIn addition to its comprehensive scientific program\, the summit offers extensive networking opportunities designed to foster collaboration across the autoimmune cell therapy community. Attendees will have the chance to connect with peers\, potential partners\, investors\, solution providers\, and key opinion leaders who are addressing similar scientific\, clinical\, operational\, and commercial challenges. Through interactive roundtable discussions\, dedicated networking sessions\, and informal meetings\, participants can exchange ideas\, establish valuable partnerships\, and build relationships that help accelerate the development and delivery of transformative cell therapies for patients living with autoimmune diseases. \nTo know more visit: https://ter.li/j0rhnmgf
URL:https://www.pharmajournalist.com/event/4th-cell-therapy-for-autoimmune-disease-summit/
LOCATION:Hilton Philadelphia City Avenue\, 4200 City Ave\, Philadelphia\, PA\, 19131\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261204
DTSTAMP:20260827T093413Z
CREATED:20260827T093413Z
LAST-MODIFIED:20260827T093413Z
UID:44259-1796083200-1796342399@www.pharmajournalist.com
SUMMARY:10th Antifibrotic Drug Development Summit 2026
DESCRIPTION:Antifibrotic Drug Development Summit 2026 | December 1-3\, 2026 | Boston\, MA\, USA \nThe 10th Antifibrotic Drug Development Summit is the industry’s only dedicated forum focused on cross-indication antifibrotic drug development\, bringing together 60+ senior leaders across discovery\, preclinical\, translational\, biomarker\, and early clinical development. \nThis landmark anniversary meeting will explore how shared fibrosis biology\, predictive biomarkers\, human-relevant models\, and fibrosis resolution mechanisms can accelerate the development of next-generation therapies across lung\, liver\, kidney\, cardiac\, skin\, gut\, and systemic fibrosis indications.  \nFeaturing 23+ expert speakers from leading organizations including Madrigal Pharmaceuticals\, AbbVie\, aTyr Pharma\, Pfizer\, Takeda\, Novartis\, Arda Therapeutics\, and Tribune Therapeutics\, attendees will gain actionable insights into target identification\, translational strategies\, patient stratification\, and cross-indication expansion. \nThe event includes our highly anticipated three interactive pre-conference workshops\, two days of scientific presentations\, panel discussions\, and dedicated networking opportunities designed to foster collaboration across the fibrosis ecosystem. \nWho Should Attend? \n\nDiscovery & preclinical scientists\nTranslational researchers\nBiomarker specialists\nClinical development teams\nFibrosis-focused biotech and pharma leaders\n\nRegister and learn more: https://ter.li/5u0tkg56
URL:https://www.pharmajournalist.com/event/10th-antifibrotic-drug-development-summit-2026/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261204
DTSTAMP:20260915T005142Z
CREATED:20260915T005142Z
LAST-MODIFIED:20260915T005142Z
UID:44357-1796083200-1796342399@www.pharmajournalist.com
SUMMARY:Amylin-Based Therapeutics Summit
DESCRIPTION:Amylin‑Based Therapeutics Summit | December 1-3\, 2026 | Boston\, MA\nThe amylin analog space is rapidly expanding in 2026\, with new companies entering the field\, stealth programs beginning to emerge\, and major investment from Roche–Zealand Pharma and AbbVie–Gubra reinforcing growing confidence in the modality. With biology still being unlocked and multiple development paths on the table\, there remains headroom to define best‑in‑class amylin therapeutics\, open new indications\, and shape how this therapeutic area will deliver differentiated\, durable benefit. For companies that get the science right\, the competitive upside is significant. \nThe inaugural Amylin‑Based Therapeutics Summit 2026 arrives at this critical inflection point. This is the first and only industry‑dedicated forum bringing biopharma and academia together to dive deep and explore the full breadth of amylin drug development – from foundational receptor biology to late‑stage clinical strategy. Across two immersive days\, learn from and connect with pioneering minds from Novo Nordisk\, Eli Lilly\, Zealand Pharma\, iBio\, I2O Therapeutics and emerging innovators who are collectively shaping the field. \nView the full event guide: https://ter.li/2ao09t84
URL:https://www.pharmajournalist.com/event/amylin-based-therapeutics-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR